Introduction
============

Inherited retinal dystrophies (IRDs) are a highly heterogeneous group of disorders characterized by progressive dysfunction of photoreceptors and RPE cells. They represent the major cause of familial blindness, with more than 2 million people affected worldwide \[[@r1]\]. In general, IRDs are classified based on the type of retinal cells (cones or rods) that are primarily affected, the age of onset, and the progression of degeneration \[[@r2]\].

Cone-rod dystrophy (CRD; OMIM [120970](https://www.ncbi.nlm.nih.gov/omim/?term=120970)) and cone dystrophy (CD; OMIM [602093](https://www.ncbi.nlm.nih.gov/omim/?term=602093)) are progressive forms of IRDs with a prevalence ranging from 1/30,000 to 1/40,000 \[[@r3]\]. Whereas CRD is characterized by the progressive loss of cone function, followed by loss of rod photoreceptor function, in CD cone function decreases progressively, while rod function is normal until the late stages of the disorder. The main symptoms of CRD are decreased visual acuity, color vision defects, and photophobia, sometimes followed by the progressive loss of peripheral vision and night blindness \[[@r3]-[@r5]\]. Perifoveal atrophy of the outer retina and a "bull's eye" appearance of the retina are typically observed on fundus examination and optical coherence tomography (OCT) in patients with CRD \[[@r6]\].

Cone-rod dystrophies are genetically heterogeneous with all modes of inheritance documented. To date, ten genes for the autosomal dominant forms of CRD/CD are known: *AIPL1* (ID: 23746, OMIM: [604392](https://www.omim.org/entry/604392)), *CRX* (ID: 1406, OMIM: [602225](https://www.omim.org/entry/602225)), *GUCA1A* (ID: 2978, OMIM: [600364](https://www.omim.org/entry/600364)), *GUCY2D* (ID: 3000, OMIM: [600179](https://www.omim.org/entry/600179)), *PITPNM3* (ID: 83394, OMIM: [608921](https://www.omim.org/entry/608921)), *PROM1* (ID: 8842, OMIM: [604365](https://www.omim.org/entry/604365)), *PRPH2* (ID: 5961, OMIM: [179605](https://www.omim.org/entry/179605)), *RIMS1* (ID: 22999, OMIM: [606629](https://www.omim.org/entry/606629)) *SEMA4A* (ID: 64218, OMIM: [607292](https://www.omim.org/entry/607292)), *UNC119* (ID: 9094, OMIM: [604011](https://www.omim.org/entry/604011))*.* Twenty two genes are known to be implicated in the autosomal recessive forms: *ABCA4* (ID: 24, OMIM: [601691](https://www.omim.org/entry/601691)), *ADAM9* (ID: 8754, OMIM: [602713](https://www.omim.org/entry/602713)), *ATF6* (ID: 22926, OMIM: [605537](https://www.omim.org/entry/605537)), *C21ORF2* (ID: 755, OMIM: [603191](https://www.omim.org/entry/603191)), *C8ORF37* (ID: 157657, OMIM: [614477](https://www.omim.org/entry/614477)), *CACNA2D4* (ID: 93589 OMIM: [608171](https://www.omim.org/entry/608171)), *CDHR1* (ID: 92211, OMIM: [609502](https://www.omim.org/entry/609502)), *CERKL* (ID: 375298, OMIM: [608381](https://www.omim.org/entry/608381)) *CNGA3* (ID: 1261, OMIM: [600053](https://www.omim.org/entry/600053)), *CNGB3* (ID: 54714, OMIM: [605080](https://www.omim.org/entry/605080)), *CNNM4* (ID: 26504, OMIM: [607805](https://www.omim.org/entry/607805)), *GNAT2* (ID: 2780, OMIM: [139340](https://www.omim.org/entry/139340)), *IFT81* (ID: 28981, OMIM: [605489](https://www.omim.org/entry/605489)), *KCNV2* (ID: 169522, OMIM: [607604](https://www.omim.org/entry/607604)), *PDE6C* (ID: 5146, OMIM: [600827](https://www.omim.org/entry/600827)), *PDE6H* (ID: 5149, OMIM: [601190](https://www.omim.org/entry/601190)), *POC1B* (ID: 282809, OMIM: [614784](https://www.omim.org/entry/614784)), *RAB28* (ID: 9364, OMIM: [612994](https://www.omim.org/entry/612994)), *RAX2* (ID: 84839, OMIM: [610362](https://www.omim.org/entry/610362)), *RDH5* (ID: 5959, OMIM: [601617](https://www.omim.org/entry/601617)) *RPGRIP1* (ID: 57096 OMIM: [605446](https://www.omim.org/entry/605446)), *TTLL5* (ID: 23093, OMIM: [612268](https://www.omim.org/entry/612268))*.* The X-linked form of CRD is associated with mutations in *RPGR* (ID: 6103, OMIM: [312610](https://www.omim.org/entry/312610)) and *CACNA1F* (ID: 778, OMIM: [300110](https://www.omim.org/entry/300110); [RetNet](http://www.sph.uth.tmc.edu/RetNet)).

Most of the previously reported molecular analyses of patients affected with CRD were based on targeted Sanger sequencing of selected genes. This approach yields a low detection rate that is further confounded due to the clinical and genetic overlap between CRD and other retinal dystrophies. The detection rate (or diagnostic yield) in CRD has increased since the introduction of next-generation sequencing (NGS) technologies, including the targeted capture of known disease genes ("disease panels"), whole exome sequencing (WES), and whole genome sequencing (WGS). Apart from searching for new mutations in the known genes, WES and WGS give the opportunity to discover novel genes associated with CRD \[[@r7]\]. It has recently been discovered that some unsolved cases with IRD can be attributed to copy number variations (CNVs) and noncoding variants. Moreover, some IRD genes appeared to be CNV-prone \[[@r8],[@r9]\]. NGS-based technologies, especially WGS, but also disease panels and WES, can be applied as a useful tool for detecting CNVs \[[@r10]-[@r12]\]. The aim of this study was to determine the underlying genetic defect of the disease in 18 Polish families with CRD (37 patients).

Methods
=======

Selection of patients
---------------------

A total of 37 patients from 18 families of Polish origin were recruited for this study, having previously been clinically diagnosed with CRD based on the following criteria: early childhood decrease of visual acuity, photophobia, decreasing scotopic electroretinogram (ERG) amplitudes, color vision defects, and progressive loss of central vision (central scotoma). All patients had a positive family history compatible with autosomal dominant inheritance (AD, seven families), autosomal recessive inheritance (AR, five families), X-linked recessive inheritance (XL, three families), or either autosomal recessive or X-linked recessive inheritance (AR/XL, three families).

The study complied with the tenets of the Declaration of Helsinki and the Association for Research in Vision and Ophthalmology (ARVO) statement on human subjects, it was also approved by the Poznan University of Medical Sciences Institutional Review Board. Written informed consent was obtained from all participants or their legal guardians.

Molecular genetic analysis
--------------------------

Venous blood was collected from all index cases, as well as from affected and unaffected available family members (the total number of samples analyzed was 75). Genomic DNA was isolated from leukocytes according to the conventional salting-out procedure \[[@r13]\].

A total of six families, including three families with X-linked recessive inheritance and three families with either autosomal recessive or X-linked recessive inheritance, were screened for mutations in the *RPGR-ORF15* ([NM_001331041](https://www.ncbi.nlm.nih.gov/nuccore/NM_001331041)) gene using Sanger sequencing ([Asper Biotech](http://www.asperbio.com), Tartu, Estonia).

APEX-arrayed primer extension for *ABCA4* ([NM_000350](https://www.ncbi.nlm.nih.gov/nuccore/NM_000350)) gene variants was performed in five families (Families 3, 5, 6, 12, and 17) with an AR mode of inheritance and in two families (Families 11 and 15) with either the AR or XL mode of inheritance (Asper Biotech). The version of the APEX array applied was designed to cover 558 variants in the *ABCA4* gene.

A patient from Family 3 carrying a single heterozygous variant in the *ABCA4* gene was screened further for possible structural rearrangements using multiple ligation probe analysis (MLPA; SALSA MLPA P151 ABCA4 mix-1 probemix and SALSA MLPA P152 ABCA4 mix-2 probemix) according to the manufacturer's instructions ([MRC](http://www.mlpa.com)-Holland, Amsterdam, Netherlands). Sanger sequencing for the most common deep intronic variants V1-V7 in the *ABCA4* gene (V1: c.5196+1137G\>A, V2: c.5196+1216C\>A, V3: c.5196+1056A\>G, V4: 4539+2001G\>A, V5: 4539+2028C\>T, V6: 6342G\>A, V7: 4773+3A\>G) which may affect the correct splicing was performed as described earlier \[[@r14]\]. The primer sequences are available upon request.

PCR products were purified using ExoSAP-IT (Exonuclease I and Shrimp Alkaline Phosphatase Cleanup for PCR products, Affymetrix, [ThermoFisher](http://www.thermofisher.com)) and directly sequenced using Dye Terminator chemistry (v3.1 BigDye^®^Terminator, Life Technologies). For verification of variants identified by targeted NGS and WES, as well as for amplification of intronic variants V1-V7 in the ABCA4 gene the following PCR conditions were applied: 95 °C, 3 min (preliminary denaturation); 40 cycles of denaturation at 94 °C for 30 s, annealing for 30 s with temperature starting from 63 °C, decreasing to 55 °C (touchdown PCR −0.2 °C per cycle), elongation at 72 °C for 45 s; and the final synthesis at 72 °C, 10 min. PCR was run in a Mastercycler pro thermocycler (Eppendorf, Hamburg, Germany) using HiFiTaq polymerase (Novazym, Poznan, Poland)The sequencing products were separated on an ABI 3130xl capillary sequencer Genetic Analyzer (Applied Biosystems).

Seven families with the AD mode of inheritance, five families with the AR mode of inheritance, and two families with either the AR or X-linked recessive (one patient from each family) mode of inheritance were analyzed using a targeted NGS diagnostic panel for eye diseases. Targeted NGS of retinal disease--associated genes was performed at [CeGaT](http://www.cegat.de) (Center for Genomics and Transcriptomics, Tuebingen, Germany). A capture panel of 105 inherited retinal disease--associated genes (IRD panel) was used.

Details of the panel design, library preparation, and capture sequencing have been published \[[@r15]\]. Visualization of the CNV variants was performed using the Integrative Genomics Viewer (IGV) software \[[@r16]\]. All putative disease-causing variants were validated with Sanger sequencing. The sequence variants identified were then cross-checked to the Human Gene Mutation Database ([HGMD](http://www.hgmd.cf.ac.uk/ac/index.php)), the [Exome Variant Server](http://evs.gs.washington.edu/EVS) (NHLBI Exome Sequencing Project ESP), the [1000 Genomes Project database](http://www.internationalgenome.org/) (1000 Genomes Project Consortium 2012) and [gnomAD](http://gnomad.broadinstitute.org/) (genome Aggregation Database). In silico analysis using Sorting Intolerant from Tolerant ([SIFT](http://sift.jcvi.org)), [PolyPhen-2](http://genetics.bwh.harvard.edu/pph2), [Panther](http://pantherdb.org), and [MutationTaster](http://www.mutationtaster.org) software was performed to predict the possible effect of the novel missense mutations. [NetGene2](http://www.cbs.dtu.dk/services/NetGene2/) and [ESE software](http://krainer01.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi?process=home) packages were used to predict the outcome of splice-site mutations. Novel variants identified in this study were classified according to American College of Medical Genetics and Genomics (ACMG) guidelines \[[@r17]\]. Segregation analysis for the presence and independent inheritance of altered alleles was performed in the families with potentially causative variants in *PROM1* ([NM_006017](https://www.ncbi.nlm.nih.gov/nuccore/NM_006017)), *CNGB3* ([NM_019098](https://www.ncbi.nlm.nih.gov/nuccore/NM_019098)), *PRPH2* ([NM_000322](https://www.ncbi.nlm.nih.gov/nuccore/NM_000322)), and *GUCA1A* ([NM_001319061](https://www.ncbi.nlm.nih.gov/nuccore/NM_001319061)) genes with Sanger sequencing of the appropriate exons.

Due to financial constraints, and based on patient consent, only four families who lacked disease-causing mutations after the IRD panel analysis were selected for WES. A duo-based WES (two affected family members) was performed in one family with the AD mode of inheritance (Family 4). Exomes were enriched using the SureSelect XT Human All Exon 50 Mb kit, version 4 or 5 ([Agilent Technologies](http://www.agilent.com), Santa Clara, CA), and sequenced on the HiSeq 2500 system ([Illumina](http://www.illumina.com), San Diego, CA). Sequencing data were analyzed as previously described \[[@r7]\]. ExomeDepth version 1.0.0 was used for CNV calling \[[@r18]\]. WES was also conducted in one family with the AR mode of inheritance (Family 17) and two families with the AR/XL mode of inheritance (Families 11 and 15), but in contrast to the family with the AD mode of inheritance, only one affected patient was analyzed per family. WES in families with AR and AR/XL CRD was performed using the Nextera Rapid Capture Exome Kit (Illumina) and paired-end sequencing (2 × 100 bp) on an Illumina HiSeq 1500 instrument. Sequencing data were analyzed according to the previously described procedure in agreement with the Broad Institute recommendations \[[@r19]\]. CNVkit was used to search for CNVs in whole exome Illumina data; 42 reference samples had been preanalyzed for statistics of target (exome) bins of size 300 bp (or single exon size if shorter) and of antitarget bins of size up to 100,000 bp \[[@r20]\]. Each sample alignment .bam file, hg19 realigned, was analyzed with CNVkit using the CBS segmentation algorithm with the p value threshold set to 0.0001 (default) \[[@r21],[@r22]\]. CNV segments were reported if their real-value copy number computed from the log2 ratio was 0.2 higher or lower than neutral. Usually, the segments were subjected to further analysis only if the difference was greater than 0.5.

Candidate variants were validated and tested for cosegregation within a family using Sanger sequencing. The pedigrees of the families with CRD are presented in [Figure 1](#f1){ref-type="fig"} and Appendix 1. The diagnostic strategy used in patients with CRD is presented in [Figure 2](#f2){ref-type="fig"}.

![Pedigrees and genotyping results of families with CRD whose genetic background of the disease has been identified. The genotypes are provided for all subjects available for molecular genetic analysis. Family number and disease-causing variant(s) are noted above each pedigree. Wild-type variants are indicated with +, while disease-causing variant(s) are indicated with M1 and M2.](mv-v24-326-f1){#f1}

![Diagnostic strategy used in patients with CRD.](mv-v24-326-f2){#f2}

Results
=======

Clinical features
-----------------

All patients showed typical CRD signs and symptoms: photophobia, decreased visual acuity, and color vision defects. The flash ERG scotopic and photopic responses of a typical patient are shown in [Figure 3](#f3){ref-type="fig"}. Ophthalmological findings of the indexes are summarized in [Table 1](#t1){ref-type="table"}.

![ERG data from a patient with CRD (Family 9). The left panel shows the electroretinograms (ERGs) of a normal healthy individual; the right panel shows the ERGs of the patient, which show the extinguished rod and cone response.](mv-v24-326-f3){#f3}

###### Ophthalmological findings of CRD patients.

  **Family**   **Gender**   **Age (yrs)**   **Inheritance**   **BCVA** **right-left**   **Fundus/AF**                                                     **Color Vision disturbances**   **Nyctalopia**   **Nystagmus**   **Photophobia**   **Perimetry**                             **ERG**
  ------------ ------------ --------------- ----------------- ------------------------- ----------------------------------------------------------------- ------------------------------- ---------------- --------------- ----------------- ----------------------------------------- ---------------------------------------------------
  1            M            29              XL                0.1--0.1                  pale optic disc                                                   \+                              \-               \+              \+                ND                                        photopic and scotopic diminished
  2            F            53              AD                0.02- 0.02                normal                                                            \+                              \-               \-              \-                concentric narrowed                       ND
  3            F            33              AR                0.2--0.3                  bull\'s eye maculopathy                                           \+                              \-               \-              \+                normal                                    photopic diminished, scotopic slightly diminished
  4            M            27              AD                0.2--0.2                  bilateral mild changes                                            \+                              \-               \-              \+                visual field deficit                      photopic and scotopic diminished
  5            M            17              AR                0.4- 0.4                  bilateral macular granular appearance                             \+                              \+               \-              \+                concentric narrowed                       photopic extinguished, scotopic 50%
  6            F            16              AR                0.1--0.1                  ND                                                                \+                              \-               \+              \+                ND                                        photopic 15%, scotopic 5%
  7            M            50              XL                0.05- 0.1                 bull\'s eye maculopathy                                           \+                              \-               \-              \+                central scotoma                           photopic extinguished, scotopic diminished
  8            M            24              XL                0.1--0.1                  normal                                                            \-                              \-               \+              \+                ND                                        photopic and scotopic diminished
  9            F            36              AD                0.3--0.3                  bull's eye maculopathy                                            \+                              \+               \-              \-                irregular scotomas                        photopic and scotopic diminished
  10           F            35              AD                0.1- 0.1                  bilateral pale optic disc                                         \+                              \-               \+              \+                ND                                        photopic and scotopic extinguished
  11           M            43              AR,XL             0.06- 0.1                 loss of macular reflex/ RPE atrophy                               \+                              \-               \+              \+                visual field deficit, mostly peripheral   ND
  12           F            20              AR                0.2--0.3                  normal                                                            \+                              \-               \+              \+                ND                                        photopic diminished, scotopic 50%
  13           M            38              AR,XL             0.6- 0.9                  bull\'s eye maculopathy, narrowing of the retinal blood vessels   \+                              \+               \-              \+                irregular scotomas                        photopic and scotopic diminished
  14           F            13              AD                0.1- 0.1                  loss of macular reflex, pale optic disc                           \-                              \+               \+              \-                ND                                        photopic and scotopic diminished
  15           M            20              AR,XL             0.2- 0.2                  macula with reflex, normal optic disc and blood vessels           \-                              \-               \-              \-                normal                                    photopic residual, scotopic subnormal
  16           F            45              AD                0.1- 0.1                  normal/ RPE atrophy, macular granular appearance                  \+                              \+               \+              \+                concentric narrowed (5°)                  photopic and scotopic diminished
  17           M            9               AR                0.1--0.2                  loss of macular reflex, foveal hypoplasia                         +/−                             \-               \-              \+                ND                                        extinguished photopic and diminished scotopic
  18           F            34              AD                0.1- 0.1                  bilateral macular granular appearance                             \+                              \-               \-              \+                central irregular scotomas                photopic diminished, scotopic 50%--80%

ND -- no data. Grey color indicates the first symptom reported by the patient

Molecular genetic findings
--------------------------

### Patients with the AD mode of inheritance

Molecular results for the patients with CRD are summarized in [Table 2](#t2){ref-type="table"}. The IRD panel was performed in seven families with the AD mode of inheritance.

###### Variants identified in CRD patients together with the analyses performed.

  **Family no.**                                            **Analysis**   **Gene**   **Variant classification**   **Genotype**   **Reference**                                                                                                                               
  --------------------------------------------------------- -------------- ---------- ---------------------------- -------------- --------------- ----------------------------------------------------------------------------------------------- --------------------------- --------------------------------------
  **Dominant inheritance**                                                                                                                                                                                                                                                    
  9                                                         \-             \-         \+                           \-             *PRPH2*         c.592A\>C, p.(Ser198Arg; pathogenic II)                                                         heterozygous                \[a\]
  18                                                        \-             \-         \+                           \-             *GUCA1A*        c.312C\>A, p.(Asn104Lys)                                                                        heterozygous                Jiang et al., 2008
  **Recessive inheritance**                                                                                                                                                                                                                                                   
  5                                                         \-             \+         \+                           \-             *PROM1*         c.1612delT, p.(Trp538Glyfs\*15; pathogenic Ia) c.2389dupG, p.(Ile798Hisfs\*20; pathogenic Ia)   heterozygous heterozygous   \[a\] \[a\]
  12                                                        \-             \+         \+                           \-             *CNGB3*         c.819_826del8, p.(Arg274Valfs\*13) gnomAD browser prevalence: 0.0001185                         homozygous                  Sundin et al. 2000
  17                                                        \-             \+         \+                           \+             *ATF6*          c.1691A\>G, p.(Asp564Gly; pathogenic II)                                                        homozygous                  \[Skorczyk-Werner et al., 2017\] ^1^
  **Recessive inheritance -- single mutation identified**                                                                                                                                                                                                                     
  3                                                         \-             \+         \+                           \-             *ABCA4*         c.5882G\>A, p.(Gly1961Glu) gnomAD browser prevalence: 0.003931                                  heterozygous                Allikmets et al. 1997
  6                                                         \-             \+         \+                           \-             *CNGB3*         c.1148delC, p.(Thr383Ilefs\*13) gnomAD browser prevalence: 0.002810                             heterozygous                Sundin et al. 2000
  **X -- linked inheritance**                                                                                                                                                                                                                                                 
  13                                                        \+             \-         \-                           \-             *RPGR -ORF15*   c.3142_3143dupAA, p.(Glu1049Argfs\*41; pathogenic Ic)                                           hemizygous                  \[a\]
  7                                                         \+             \-         \-                           \-             *RPGR -ORF15*   c.2716G\>T, p.(Glu906\*)                                                                        hemizygous                  Sharon et al. 2003

\[a\] -- this study; ^1^-- identified in this study, but already published; ; + molecular analysis was performed, - molecular analysis was not performed; Variants designation is based on [NM_000322](https://www.ncbi.nlm.nih.gov/nuccore/NM_000322) for *PRPH2*, [NM_001319061](https://www.ncbi.nlm.nih.gov/nuccore/NM_019098) for *GUCA1A,* [NM_006017](https://www.ncbi.nlm.nih.gov/nuccore/NM_006017) for *PROM1,* [NM_019098](https://www.ncbi.nlm.nih.gov/nuccore/NM_019098) for *CNGB3,* [NM_007348](https://www.ncbi.nlm.nih.gov/nuccore/NM_007348) for *ATF6,* [NM_000350](https://www.ncbi.nlm.nih.gov/nuccore/NM_000350) for *ABCA4* and [NM_001331041](https://www.ncbi.nlm.nih.gov/nuccore/NM_001331041) for *RPGR-ORF15* (GRCh38). Classification of novel variants according to American College of Medical Genetics and Genomics (ACMG) guidelines. The gnomAD browser prevalences are provided for mutated alleles in non-Finnish Europeans.

NGS revealed potentially causative variants in genes associated with the AD form of CRD in Families 9 and 18. In Family 9, a novel nucleotide variant c.592A\>C, p.(Ser198Arg) in exon 2 of the *PRPH2* gene was identified, verified with Sanger sequencing ([Figure 4A](#f4){ref-type="fig"}), and validated with segregation analysis ([Figure 1](#f1){ref-type="fig"}). In silico analyses indicated that the substitution is probably damaging.

![Chromatograms showing three novel variants identified in patients with  CRD. **A**: Sequence trace of the *PRPH2* gene (fragment of exon 2) in  the affected individual (Family 9) carrying a heterozygous missense variant  c.592A\>C (upper panel) and a normal control individual (lower panel). **B**:  Sequence trace of the *PROM1* gene (fragment of exon 14) in the affected individual  (Family 5) carrying the heterozygous frameshift change c.1612delT (upper panel)  and a normal control individual (lower panel). **C**: Sequence trace of the *PROM1*  gene (fragment of exon 23) in the affected individual (Family 5) carrying the  heterozygous frameshift change c.2389dupG (upper panel) and a normal  control individual (lower panel). Because the *RPGR-ORF15* gene was sequenced commercially by Asper Biotech (Tartu, Estonia), the chromatogram is not available. The chromatogram showing the mutation c.1691A\>G in the *ATF6* gene was included in our previous report \[[@r19]\].](mv-v24-326-f4){#f4}

One previously described substitution c.312C\>A, p.(Asn104Lys) in the *GUCA1A* gene was discovered in Family 18 \[[@r23]\]. WES analysis performed in Family 4 did not allow identification of potentially causative variants that segregate with disease.

### Patients with the XL and XL/AR modes of inheritance

Sanger sequencing of the *RPGR-ORF15* was performed in three families (Families 1, 7, and 8) presenting with an XL mode of inheritance and in three additional families (Families 11, 13, and 15) with the AR/XL mode of inheritance. Sequence analysis of the *RPGR-ORF15* revealed two hemizygous variants in two families (7 and 13). In Family 13, we identified a novel indel variant c.3142_3143dupAA, p.(Glu1049Argfs\*41) resulting in a frameshift and premature termination of translation. Unfortunately, parental genomic DNA was unavailable for allelic segregation analysis. The known nonsense change c.2716G\>T, p.(Glu906\*) was identified in Family 7 \[[@r24]\]. Commercial sequencing electropherograms from Asper Biotech were not available for inclusion in [Figure 4](#f4){ref-type="fig"}.

### Patients with the AR mode of inheritance

Five families with AR CRD (Families 3, 5, 6, 12, and 17) and two families with XL/AR CRD negative for variants in the *RPGR-ORF15* gene (Families 11 and 15) were screened for variants in the *ABCA4* gene using APEX analysis. The APEX analysis revealed an alteration in *ABCA4* in only one family (Family 3). A previously described missense variant, c.5882G\>A, p.(Gly1961Glu), was present in the heterozygous state in the female index patient \[[@r25]\]. To exclude any copy number variations, such as large deletions/duplications, MLPA was performed within the *ABCA4* gene in this family. However, no genomic rearrangements were found in the *ABCA4* gene. In addition, several deep intronic variants (V1--V7) in the *ABCA4* gene, which may affect gene splicing, have been reported to segregate with the disease \[[@r14]\]. The analysis of these sites did not reveal the presence of any of these intronic variants. As the absence of an alteration on a second allele of the *ABCA4* gene did not allow the molecular diagnosis, the proband was referred for a further molecular analysis.

All families with the AR mode of inheritance (3, 5, 6, 12, and 17) and the families with the AR/XL mode of inheritance (11 and 15) were submitted for IRD panel--based NGS. NGS allowed the identification of putative sequence variants in three families (5, 6, and 12) and confirmed the previously identified *ABCA4* heterozygous variant in Family 3. In Family 5, two novel frameshift variants in the *PROM1* gene were identified: c. 1612delT, p.(Trp538Glyfs\*15) in exon 14 ([Figure 4B](#f4){ref-type="fig"}) and c.2389dupG, p.(Ile798Hisfs\*20) in exon 23 ([Figure 4C](#f4){ref-type="fig"}) in the form of a compound heterozygote ([Figure 1](#f1){ref-type="fig"}). Both variants had not been described in scientific literature previously and were not functionally tested for potential pathogenicity.

In Family 12, a previously reported homozygous frameshift variant c.819_826del8, p.(Arg274Valfs\*13) in exon 6 of the *CNGB3* gene was detected ([Figure 1](#f1){ref-type="fig"}) \[[@r26]\].

In Family 6, NGS revealed a previously described heterozygous frameshift variant c.1148delC, p.(Thr383Ilefs\*13) in exon 10 of the *CNGB3* gene \[[@r26]\].

Three families who remained unsolved with targeted NGS including one with the AR mode of inheritance (Family 17) and two with the AR/XL mode of inheritance (Families 11 and 15) were subject to WES. WES allowed the genetic basis of the retinal dystrophy in one family to be identified (Family 17): a novel variant c.1691A\>G, p.(Asp564Gly) in the *ATF6* gene, which we reported to be pathogenic \[[@r19]\]. None of the novel variants identified based on the combined strategy of Sanger sequencing and the NGS technique was found in a control cohort annotated in the Exome Variant Server (EVS) database (Exome Variant Server 2015) or in the 1000 Genomes Project database (1000 Genomes Project Consortium 2012), ExAC Browser Beta (Exome Aggregation Consortium 2015), and gnomAD browser beta (genome Aggregation database).

Discussion
==========

In this study, we present the results of molecular screening in 18 Polish families who have CRD. Notably, this is the first report on the spectrum of disease genes and pathogenic variants causing CRD in a Polish population. In total, we identified the most likely genetic cause of disease in seven families ([Table 2](#t2){ref-type="table"}).

Sequencing of the *RPGR-ORF15* gene, performed in families with the XL and AR/XL modes of inheritance, resulted in the identification of two variants in two families (Families 7 and 13). Interestingly, the patient from Family 7, with a known nonsense change c.2716G\>T, p.(Glu906\*) presented a more severe course of the disease (refer to the earlier age of onset and worse visual acuity) than the patient from Family 13, with a frameshift variant.

Depending on the population and its ethnic background, mutations in the *ABCA4* gene have been shown to be the most prevalent cause of AR CRD, accounting for 30--60% cases \[[@r27]\]. The carrier frequency is estimated at around 2% in the general population, although some studies suggest that the frequency might be considerably higher and account for even 5--20% of individuals \[[@r27]-[@r31]\]. The APEX analysis revealed an *ABCA4* alteration in only one family (Family 3) \[[@r25]\]. Taking into consideration the high *ABCA4* mutation carrier frequency, the presence of the variant on one allele is not sufficient to confirm the molecular diagnosis. This finding suggests that *ABCA4* plays a minor role in Polish patients with AR CRD. One of the possible reasons for these discrepancies and the main limitation of the study was the small size of the study group. Fourteen families involved in this study were examined with targeted NGS with the application of a custom IRD panel, which allowed a possible genetic cause to be identified in four out of 14 families.

The variant reported in Family 12, c.819_826del8, p.(Arg274Valfs\*13) in the *CNGB3* gene, has been previously reported as a recurrent mutation in families with achromatopsia, although only in a compound heterozygous state with another, usually missense variant \[[@r9],[@r32]-[@r36]\]. Mutations in the *CNGB3* gene are also known to be a rare cause of AR CRD, described thus far in only six families \[[@r37]-[@r39]\]. All the reported AR CRD cases have been found to be homozygous for frameshift or splice-site mutations. Therefore, it is possible that c.819_826del8, p.(Arg274Valfs\*13) in a homozygous state is the cause of AR CRD in Family 12.

The missense variant c.592A\>C identified in the *PRPH2* gene of the patient from Family 9 has not been reported before, but the substitution in the same codon (AG**C**\>AG**G**) c.594C\>G resulting in the same amino acid change p.(Ser198Arg) has been previously identified as a likely pathogenic in two families who have an autosomal dominant form of retinitis pigmentosa (RP) \[[@r40],[@r41]\]. The missense substitution p.(Ser198Arg) is localized in the large intradiscal loop domain (D2) of the peripherin-2 protein, at an evolutionary conserved amino acid position. The D2 loop plays a crucial role in the dimerization of homo- and heterotetramers with ROM1, which is critical for PRPH2-ROM1 interactions important for the formation and stabilization of photoreceptor outer segments \[[@r41],[@r42]\]. The previously reported results of in silico analyses (PolyPhen and SIFT software) for the p.(Ser198Arg) substitution, as well as the analysis (Mutation Taster software) for the variant c.592A\>C (this study) indicates that the substitution is probably damaging. However, additional functional analyses are required to confirm the pathogenicity of the p.(Ser198Arg) variant. Notably, the substitution c.594C\>G, p.(Ser198Arg) has been identified to date only in families affected by AD RP \[[@r40],[@r41]\].

In Family 6, NGS on the IRD panel revealed a previously described heterozygous frameshift variant c.1148delC, p.(Thr383Ilefs\*13) in exon 10 of the *CNGB3* gene \[[@r26]\]. The lack of a second allele in this patient might be explained in several ways. First, NGS on the retinal panel does not allow large genomic rearrangements in the heterozygous state to be identified. Recently, the prevalence of CNVs in the *CNGB3* gene was determined to be approximately 2% of all cases \[[@r9]\]. Moreover, according to Mayer et al., CNVs can account for more than one-third of unknown mutations in patients with single heterozygous mutations upon Sanger sequencing \[[@r8],[@r9]\]. There is also a possibility that the missing variant is located deep inside the intron, disturbing the proper splicing or expression of the *CNGB3* gene. Finally, taking into consideration that the carrier frequency for *CNGB3* mutations is estimated at about 1:200 births, the members of Family 6 could possibly be only carriers, and a causative mutation is located in another gene \[[@r32]\]. Due to the lack of color vision defects, clinical diagnosis of achromatopsia was excluded.

In one family with AR CRD (Family 5), we identified two novel variants in the *PROM1* gene. Missense mutations in the *PROM1* gene have mostly been associated with autosomal dominant forms of Stargardt-like macular dystrophy, bull's eye macular dystrophy, and cone-rod dystrophy. To date, only a few cases of nonsense, frameshift, and intronic mutations have been described in patients with severe forms of autosomal recessive CRD and retinitis pigmentosa \[[@r43]-[@r49]\]. Both variants identified in this family result in frameshift mutations and the occurrence of a premature termination codon. The derived proteins are substantially shortened, lacking the important transmembrane domain. Therefore, the pathogenicity of these mutations is highly probable.

The mutation detection rate for the IRD panel applied was 38% (8/21 alleles), which is lower in comparison with previous studies that used the same IRD panel in a larger cohort of patients with various retinal dystrophies, where the overall detection rates were 55% and 50% for the group of patients with CRD \[[@r7],[@r15]\]. The lower detection rate for the panel-based analysis can be explained in several ways. The present study group was smaller than the cohorts analyzed in previous reports. Moreover, the spectrum of CRD disease genes and mutations may differ from that of Western European countries and the United States, which was the basis for the preparation of the custom IRD NGS panel. In addition, the version of the IRD panel applied for the families in the present study encompassed only CRD genes that were known at that time (22 genes). To date, 12 more genes and loci that had not been incorporated in that version of the panel have been found to be associated with CRD: *ATF6, CNGA3, CNNM4, C21ORF2, C8ORF37, GNAT2, ITF81, PDE6H, POC1B, RAB28,* and *TTLL5* ([RetNet](http://www.sph.uth.tmc.edu/RetNet)). Therefore, we cannot exclude variants in these genes in families who have not been examined with WES.

Four families of the families who had been mutation-negative upon analysis with the IRD panel were selected for WES, which allowed the causative change in one family with the autosomal recessive mode of inheritance to be identified \[[@r19]\]. However, it is not reasonable to assess the mutation detection rate for WES, as this analysis was not performed in all the families.

Searches for CNVs in WES data have not revealed any potentially causative variations. As this analysis was performed only for WES data and not a targeted NGS panel, we cannot exclude CNVs in families who have not undergone WES. The presence of mutations in non-coding regions, or deep intronic mutations, which have been reported to date as a cause of retinal dystrophies cannot be excluded in the group as a whole, either \[[@r9],[@r14],[@r50]\]. As these types of mutations are not possible to detect with the use of WES, the families who are negative for WES should be further analyzed with whole genome sequencing. These studies confirm that the NGS on the retinal panel seems to be a more effective method for diagnosis of the molecular basis of CRD, compared to other methods, including Sanger sequencing \[[@r7],[@r15]\].
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Pedigrees of the CRD families whose genetic background of the disease remained unexplained, with the exception of Family 17 (molecular results were reported previously). To access the data, click or select the words "[Appendix 1](http://www.molvis.org/molvis/v24/appendices/mv-v24-326-app-1.jpg)."
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